SC
UTHR icon

Savant Capital’s United Therapeutics UTHR Stock Holding History

Savant Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Buy
3,845
+1,519
+65% +$855K 0.01% 590
2026
Q1 		$1.38M Buy
2,326
+463
+25% +$231K 0.01% 523
2025
Q4 		$908K Hold
1,863
– – 0.01% 618
2025
Q3 		$781K Buy
+1,863
New +$627K ﹤0.01% 645
2025
Q1 		– Sell
-10,205
Closed -$3.6M – 1417
2024
Q4 		$3.6M Buy
10,205
+266
+3% +$97.8K 0.03% 291
2024
Q3 		$3.56M Buy
9,939
+199
+2% +$67.2K 0.03% 286
2024
Q2 		$3.1M Sell
9,740
-122
-1% -$32.3K 0.03% 279
2024
Q1 		$2.27M Buy
+9,862
New +$2.23M 0.03% 329

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Savant Capital's UTHR Position: Q2 2026 in Review

Savant Capital increased its United Therapeutics (UTHR) stake by 65% in Q2 2026, buying an estimated $855K and bringing the position to 3,845 shares worth $2.18M. The position accounts for 0.01% of the portfolio, ranked #590.

Savant Capital first reported a position in UTHR in Q1 2024 and has held it in 8 quarters since. The position peaked at $3.6M in Q4 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Savant Capital held 3,845 shares of United Therapeutics worth $2.18M as of Q2 2026.
  • Savant Capital bought 1,519 United Therapeutics shares in Q2 2026, an estimated $855K.
  • United Therapeutics made up 0.01% of Savant Capital's portfolio in Q2 2026, its #590 holding.
  • Savant Capital first reported a position in United Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Savant Capital's United Therapeutics position peaked at $3.6M in Q4 2024.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.